GLPwatch
Papers (10382)
Page 114 of 174, ranked by citation count.
- Treatment of Bile Acid Diarrhea With Glucagon-Like Peptide 1 Receptor Agonists: A Promising Yet Understudied Approach.
- Peptides originally derived from Chilobrachys jingzhao tarantula venom possess beneficial effects on pancreatic beta cell health and function.
- Poly(l-threonine-<i>co</i>-l-threonine Succinate) Thermogels for Sustained Release of Lixisenatide.
- PIONEER REAL Spain: A multicentre, prospective, real-world study of oral semaglutide use in adults with type 2 diabetes.
- Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide.
- Interleukin-1β in circulating mononuclear cells predicts steatotic liver disease improvement after weight loss in subjects with obesity and prediabetes or type 2 diabetes.
- Idiopathic intracranial hypertension: expanding our understanding.
- Real-world effectiveness of Semaglutide treatment on weight loss maintenance after weight loss in patients with obesity or overweight and diabetes.
- The impact of semaglutide on fusion rates following posterior lumbar fusion surgery in patients with type 2 diabetes.
- Tirzepatide for Patients With Type 2 Diabetes.
- Tirzepatide highly effective for weight loss.
- Semaglutide 2.4-mg injection as a novel approach for chronic weight management.
- Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.
- Smoke or fire? Acute pancreatitis and the liraglutide trials.
- Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients.
- Retatrutide: a triple incretin receptor agonist for obesity management.
- Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL.
- Tirzepatide for type 2 diabetes.
- Quantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis.
- Impact of semaglutide on weight and functional outcomes among obese heart failure patients: a propensity scores matching analysis.
- Microglia Involvement into Acute and Chronic Brain Damage in Diabetic Rats: Impact of GLP-1RA and SGLT-2i.
- Recombinant Expression and Stapling of a Novel Long-Acting GLP-1R Peptide Agonist.
- A comprehensive study on the identification and characterization of major degradation products of synthetic liraglutide using liquid chromatography-high resolution mass spectrometry.
- Exendin-4 promotes actin cytoskeleton rearrangement and protects cells from Nogo-A-Δ20 mediated spreading inhibition and growth cone collapse by down-regulating RhoA expression and activation via the PI3K pathway.
- Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
- Review of pharmacotherapy options for the management of obesity.
- Efficacy and safety of once-weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial.
- Sleeve-to-bypass conversion vs. sleeve-with-adjuvant GLP-1 receptor agonists: an academic multicenter retrospective study.
- GLP-1 receptor agonist protects glucose-stimulated insulin secretion in pancreatic β-cells against lipotoxicity via PPARδ/UCP2 pathway.
- Integrated expression profiles of mRNA and miRNA in a gerbil model of fatty liver fibrosis treated with exenatide.
- Semaglutide for Weight Loss.
- Glucometabolic control of once-weekly dulaglutide switched from DPP4 inhibitor versus daily empagliflozin add-on in patients with type 2 diabetes inadequately controlled with metformin, sulfonylurea, and DPP4 inhibitor: A randomised trial.
- Exendin-4 affects calcium signalling predominantly during activation and activity of beta cell networks in acute mouse pancreas tissue slices.
- Semaglutide for the treatment of cognitive dysfunction in major depressive disorder: A randomized clinical trial.
- Optimized LC-MS/MS method for quantifying insulin degludec and liraglutide in rat plasma and Tissues: Application in pharmacokinetics and biodistribution.
- Comparative effectiveness of GLP-1 receptor agonists on cardiovascular outcomes among adults with type 2 diabetes and moderate cardiovascular risk: emulation of a target trial.
- The GLP1R Agonist Semaglutide Inhibits Reactive Astrocytes and Enhances the Efficacy of Neural Stem Cell Transplantation Therapy in Parkinson's Disease Mice.
- Comparison of Dapaglifozin and Liraglutide in Patients with Poorly Controlled Type 2 Diabetes Mellitus: a 24-week, Open, Double-centered, Head to Head Trial.
- The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 months.
- Glucagon-like peptide-1 receptor agonists for the treatment of opioid use disorders: a systematic review.
- Preoperative Glucagon-Like Peptide-1 Receptor Agonists and Bariatric Surgery Outcomes: A Systematic Review.
- Peptide complex containing GLP-1 exhibited long-acting properties in the treatment of type 2 diabetes.
- Estimating New Eligibility and Maximum Costs of Expanded Medicare Coverage of Semaglutide for Cardiovascular Risk Prevention.
- Cardiovascular outcomes and safety of semaglutide in non-overweight populations with type 2 diabetes: a comparison with dipeptidyl peptidase 4 inhibitors.
- Effect of once-weekly subcutaneous semaglutide on arterial inflammation in people with type 2 diabetes and cardiovascular disease using PET-MRI: Primary results of a randomized, double-blind, placebo-controlled trial.
- Assessment of Exenatide Extended-Release for Maintenance of Diabetic Remission in Cats.
- Pharmacologic Treatment of Obesity in adults and its impact on comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM).
- Influence of Trp-Cage on the Function and Stability of GLP-1R Agonist Exenatide Derivatives.
- Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study.
- Tirzepatide (Mounjaro) for type 2 diabetes.
- The dual incretin co-agonist tirzepatide increases both insulin secretion and glucose effectiveness in model experiments in mice.
- UK regulator warns public after seizing hundreds of fake Ozempic pens.
- Investigation of the preservation effect of canagliflozin on pancreatic beta cell mass using SPECT/CT imaging with <sup>111</sup>In-labeled exendin-4.
- Practice pearl: liraglutide and cardiovascular and renal events in type 2 diabetes.
- New insight on the role of liraglutide in alleviating dexamethasone-induced pancreatic cytotoxicity via improving redox status, autophagy flux, and PI3K/Akt/Nrf2 signaling.
- Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT-J trial.
- Comparison of twelve single-drug regimens for the treatment of type 2 diabetes mellitus.
- Exendin-4 differentially modulates essential functions of human dermal fibroblasts under normoglycemic and hyperglycemic conditions.
- Tirzepatide Reduces Fat Mass and Provides Good Glycaemic Control in Type 2 Diabetes Patients Undergoing Haemodialysis: A Single-Centre Retrospective Study.
- The impact of semaglutide use for weight loss on transforaminal lumbar interbody fusion outcomes.